Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up

Background Imatinib is a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia (CML). Cutaneous adverse reactions of imatinib therapy have been reported in 7%-88.9% patients.